Abstract 384P
Background
Betel nut chewing might contribute to strong invasion and treatment refractoriness. In western countries where HPV+ OPC prevalence is high, induction TPF response rate in locally advanced HNSCC is around 70%; Erbitux and TP (Argiris in JCO2008) response rate is 86%. In the analysis from KGMH in Taiwan, induction response for locally advanced HNSCC was 55% in betel-nuts chewers compared with 75% in non-users(p=0.038; From Su in World Journal of Surgical Oncology 2016). Erbitux-TPF induction response rate was 88% from VGH in Taiwan by Lu in Head & Neck2019. In our previous study from unresectable stage IVA & IVB betal-nuts related HNSCC patients in ASCO2023, flexible chemotherapy backbones, such as TP/DP-HDFL(weekly docetaxel or paclitaxel with cisplatin and 24-hr high dose 5-fluorouracil/leucovorin infusion) with Biotherapy(EGFR or VEGFR-targeting)or Bio-immunotherapy had encouraging induction response with favorable toxicity to conversion surgery or definite CCRT.
Methods
Hypopharyngreal cancer in Taiwan in Taiwan often had advaced stage(stage IV 70%) and double cancers easily(esp. lung cancer and esophageal cancer). We prepared to compare the outcomes of different treatment strategies in stage IVA/IVB hypophryngeal cancer, from 2012 to 2023.
Results
Table: 384P
| Treatment strategies(total 75 patients) | Definite CCRT 9 | Curative surgery then adjuvant CCRT 14(all receiving total laryngectomy & bilateral neck dissection) | Induction therapy then definite CCRT 29 | Induction therapy then curative surgery then adjuvant CCRT 23 |
| Induction response(total 52 patients) | N/A | N/A | 69%(20/29) | 87%(20/23) |
| 2-year DFS(total 64 patients) | 57.1% | 63.6% | 68% | 81% |
| 5-year OS(total 50 patients) | 20% | 26.7% | 37.5% | 50% |
All with maintenance UFUR
Conclusions
CCRT is still one standard option; if no need for organ preservation, curative surgery followed by adjuvant CCRT still works in resectable and medically operable patients. Maintenance UFUR yielded relatively favorable 2-year DFS and 5-year OS. Induction Bio-CT or Bio-chemoimmunotherapy followed by CCRT may be promoted beyond TAX323/324. Aggressive induction therapy followed by mini-invasive surgery and then adjuvant CCRT with maintenance UFUR might be administered in selected patients with high induction response. Encouraging outcomes have been shown by sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan.
Clinical trial identification
N/A
Editorial acknowledgement
Legal entity responsible for the study
Institutional Review Board in National Taiwan University Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract